Back to Results

A Phase 1, open label, first-in-human study of TR1801-ADC, an antibody drug conjugate (ADC), in patients with select solid tumors expressing c-Met

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

Tumor must express c-MET or be MET amplified

Phase

I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Wells Messersmith,  MD

Wells Messersmith, MD

Study ID

Protocol Number: 19-0232

More information available at ClinicalTrials.gov: NCT03859752

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers